四環醫藥(00460.HK)年度經調整純利跌24.8%至12.18億元 末期息1.3分
格隆匯3月24日丨四環醫藥(00460.HK)公佈,截至2019年12月31日止年度,公司實現收益28.87億元人民幣(單位下同),同比減少1.0%;毛利22.95億元,同比減少3.5%;公司擁有人應占虧損27.53億元,同期錄得盈利16.20億元,公司擁有人應占溢利(經調整)(加回減值虧損)12.18億元,同比減少24.8%;每股末期股息1.3分。
公司擁有人應占虧損約為人民幣27.53億元,主要歸因於年內(i)商譽、無形資產、使用權益法計算的投資及物業、廠房及設備之減值虧損;及(ii)集團的研發活動增加所致。加回該等減值虧損,經調整的公司擁有人應占溢利同比下降24.8%至約12.18億元。
年內,經營活動的現金流量淨額約為14.18億元。集團的負債與資本比率(即其他借款除以公司擁有人應占權益之百分比)維持低於1.0%,保持健康財務狀況。
年內,研發投入及相關活動同比上升45.7%至約7.77億元,佔集團總收益銷售額的26.9%。這主要由於研發團隊在研發方面努力成果及研發團隊擴展所致。
年內,心腦血管產品的收益同比減少12.8%至約23.43億元,佔集團總收益的81.1%,銷售減少主要由於2019年7月頒佈的重點監控藥品目錄所致。非心腦血管產品的收益同比大幅增加134.9%至約5.44億元,佔集團總收益的18.9%。銷售增加主要由於集團於年內不斷擴大增長期產品的醫院銷售量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.